Products

VisAble.IO
Techsomed
Oncology AI
VisAble.IO by Techsomed is an AI-powered software that enhances the precision of liver and kidney ablation procedures through advanced planning, real-time image guidance, and post-procedure confirmation using ultrasound, CT, and MRI.

See all 1 product →

About Techsomed

Techsomed is an Israeli medical device company specializing in AI-powered, ultrasound-based real-time monitoring systems for thermal ablation procedures. Their flagship BioTraceIO360 platform is a hardware-agnostic solution designed to unify the planning, execution, and monitoring phases of image-guided ablation therapy. This technology significantly enhances procedural precision by providing physicians with crucial real-time feedback and predictive insights into post-ablation tissue damage.

The BioTrace system integrates with standard commercial ultrasound imaging systems, as well as CT and MRI data, to visualize and analyze tissue viability during interventions. It aims to transform thermal ablation from a procedure reliant on guesswork into a precise, feedback-dependent treatment, thereby minimizing damage to healthy tissue and maximizing target tissue ablation. The company’s solutions, including BioTraceIO Vision and BioTraceIO Precision, have received FDA clearance for applications such as liver tumor ablation. Techsomed also engages in collaborations, such as a pilot with Medtronic, to further integrate its AI-powered software with existing ablation systems.

Focus Areas

Thermal ablation image-guided therapy interventional oncology liver tumor ablation kidney tumor ablation cardiology heart arrhythmia pain management radiofrequency neurotomy AI-powered software real-time monitoring treatment planning visualization precision medicine

Business Intelligence

Key InvestorsAxil Capital, Yongjin Capital, Cobro Ventures, Magna Capital Partners, Radianx Capital, Johnson & Johnson Innovation – JJDC Inc., NextLeap Ventures, SCREEN Holdings, Alfred Mann Institute at the Technion, Europa, Dennis Klinman
PartnershipsMedtronic (BioTraceIO360 software and Emprint microwave ablation system), GE HealthCare (field evaluation with LOGIQ™ ultrasound systems), Fraunhofer MEVIS (German subsidiary for R&D), Axil Capital and Screen Holdings (joint venture in Japan)
TechnologyBioTrace™ platform, BioTraceIO360, AI-powered, hardware-agnostic, ultrasound-based real-time monitoring, image analysis, computational algorithm, generative AI capabilities, leverages standard medical imaging (US, CT, MRI)
FDA Clearances3 cleared products (estimated)

What Physicians Need to Know

Interventional Oncology (Liver & Kidney Tumor Ablation)
Techsomed's BioTraceIO360u2122 platform provides real-time visualization, planning, and assessment for thermal ablation of liver and kidney tumors. It has received FDA clearance for both liver and kidney applications, addressing challenges of limited intra-procedural visibility and non-integrated technologies.
Image-Guided Therapy & Real-time Monitoring
The BioTraceIO360u2122 solution offers continuous monitoring and analysis throughout thermal ablation procedures, utilizing image data from standard ultrasound devices. It enables live tracing of various factors, including organ movement and cancerous tissue destruction, and unifies CT, MRI, and ultrasound data into an intelligent clinical workflow.
AI-Powered Software & Precision Medicine
Techsomed's software is driven by AI, including generative AI, for advanced imaging, real-time predictive modeling, and seamless workflow integration. This technology facilitates predictive margin control, dynamic treatment planning, and validation of treatments, aiming to deliver a new level of treatment precision.
Treatment Planning & Visualization
The BioTraceIO360u2122 platform, which includes components like VisAble.IO, offers 3D visualization of the ablation target within a patient-specific anatomical view. It allows for the overlay and positioning of virtual instruments and estimated ablation regions onto medical images, providing an interactive 3D view of ablation margins and missed volumes for immediate post-procedure assessment.
Key Differentiators
Techsomed stands out with its BioTraceIO solution, the first FDA-cleared ultrasound-based software for real-time tissue response prediction in liver tumor ablation, allowing physicians to 'see the invisible'. The platform is designed as a unified, multi-organ, hardware-agnostic image-guided therapy solution. Its AI-driven precision transforms guesswork into guidance, revolutionizing thermal ablation as a minimally invasive, cost-effective, and less complicated alternative to traditional treatments.
Technology Stack
The core technology revolves around the BioTraceIO360u2122 software platform (including BioTraceIO, VisAble.IO, BioTraceIO Vision, BioTraceIO Precision). It utilizes AI-powered computational algorithms and generative AI for image registration and analysis. The platform integrates data from standard imaging modalities such as ultrasound, CT, and MRI, and is hardware-agnostic, optimized to run on powerful local systems like Lenovo ThinkStation P920/P330 Tiny.
Physician Tip

For physicians, Techsomed's solutions, particularly in interventional oncology for liver and kidney tumor ablation, offer significantly enhanced precision and control through real-time predictive capabilities and AI-powered visualization. This can boost confidence in achieving complete tumor ablation while minimizing damage to healthy tissue, potentially leading to improved patient outcomes, fewer complications, and shorter recovery times. The streamlined workflow, from planning to post-treatment assessment, and the system's hardware-agnostic nature, allowing integration with existing imaging modalities, are also key benefits to consider for clinical adoption. While Techsomed mentions broader applications in cardiology and pain management, specific product details for these areas were not extensively highlighted in the provided information.

Techsomed's BioTraceIO360u2122 platform is designed for seamless integration, unifying CT, MRI, and standard ultrasound data into a single clinical workflow. It is hardware-agnostic and compatible with standard commercial ultrasound imaging systems. Notably, Techsomed has established collaborations with industry leaders such as Medtronic (integrating with their Emprintu2122 microwave ablation system) and GE HealthCare (field evaluation with LOGIQu2122 E10 Series ultrasound systems), demonstrating its ability to work within diverse medical device ecosystems.

Products by Techsomed

1 product in the directory

VisAble.IO
Techsomed
Oncology AI
VisAble.IO by Techsomed is an AI-powered software that enhances the precision of liver and kidney ablation procedures through advanced planning, real-time image guidance, and post-procedure confirmation using ultrasound, CT, and MRI.

What the Web Says

Techsomed is an Israeli medical device company founded in 2012 that specializes in AI-driven, real-time monitoring systems for thermal ablation procedures, particularly with its BioTraceIO360 platform. This platform has received FDA clearance for use in liver and kidney ablation, aiming to enhance precision and standardize minimally invasive care. While specific product reviews from G2, Glassdoor, Capterra, and Reddit for 'Techsomed' are not readily available, general employer reviews for similarly named companies like 'Technomed' and 'TechMD' on Indeed suggest a generally positive work environment with good work-life balance and culture, though some concerns about pay and management have been noted in related companies.

Overall: Mixed

Strengths

  • AI-powered real-time visualization during ablation procedures.
  • Integration with standard ultrasound devices, reducing the need for specialized hardware.
  • Multi-clinical application across oncology, cardiology, and pain management.
  • FDA clearances for BioTraceIOu2122 products validate safety and effectiveness.
  • Aims to standardize minimally invasive care from planning through verification.
  • Good work-life balance and company culture reported by employees of similarly named companies.

Limitations

  • Specific product reviews for 'Techsomed' are not easily found on major review platforms like G2, Glassdoor, Capterra, or Reddit.
  • Some employees of similarly named companies have expressed concerns regarding pay and benefits.
  • Job security and advancement received lower ratings in some related company reviews.
  • Management in some related companies received mixed reviews.

Based on reviews from: Startup Intros, Medical Product Outsourcing, Urology Times, PR Newswire, Indeed.com

Last updated: 2026-07-19

Videos

News, demos, and interviews about Techsomed.

Loading videos...

Videos load interactively. If none appear, search YouTube for Techsomed →

View all on YouTube

Press & Coverage

PR Newswire
Techsomed Receives FDA 510(k) Clearance Expanding BioTraceIO360 Platform to Kidney Ablation Advancing a Unified Multi-Organ Image-Guided Therapy Platform
Techsomed announced it received U.S. FDA 510(k) clearance for its BioTraceIO360 software platform to include percutaneous ablation of soft tissue in the kidney, in addition to its previously cleared liver application. This expands their multi-organ, hardware-agnostic image-guided therapy platform.
2025-09
AuntMinnie
Techsomed, Medtronic to collaborate on image-guided ablation therapy
Imaging AI developer Techsomed is collaborating with Medtronic to combine their BioTraceIO360 software and the Medtronic Emprint microwave ablation system for image-guided ablation therapy, assisting interventional radiologists from planning to post-treatment assessment.
2025-10
Medical Product Outsourcing
FDA OKs Techsomed's BioTraceIO360 for Kidney Ablation
Techsomed received U.S. FDA 510(k) clearance for its BioTraceIO360 software platform to include percutaneous ablation of soft tissue in the kidney, building on its existing liver clearance and advancing its multi-organ image-guided therapy platform.
2025-09
PR Newswire
Techsomed Announces FDA Clearance for Ablation Treatment Planning and Confirmation Software
Techsomed Ltd. announced it received 510(k) clearance from the US FDA for its VisAble.IO software, designed to assist physicians in planning liver ablation procedures and confirming ablation zones to increase treatment precision.
2023-09
Medical Device Network
FDA approves Techsomed's ablation treatment planning software
The US FDA granted 510(k) clearance for Techsomed's VisAble.IO software, which helps physicians plan liver ablation procedures and confirm ablation zones using 3D visualization and AI-based technology.
2023-09
BioSpace
Techsomed's BioTrace Solution Achieves De Novo Clearance from FDA as the First Ultrasound-Based Software for Tissue Response Prediction in Liver Tumor Ablation
Techsomed Medical Technologies LTD announced that the FDA granted De Novo clearance for its BioTraceIO, an ultrasound-based liver ablation software designed for tissue response prediction.
2024-01
FinSMEs
TechsoMed Raises $7M in Series B Financing
TechsoMed, an Israeli medical device company, closed a US$7M Series B equity financing round, led by Axil Capital with participation from several other investors.
2021-03
PR Newswire
Techsomed Secures $2.6M for Groundbreaking Real-time Predictive Imaging System for Thermal Ablation
Techsomed secured $2.6M in a financing round led by Johnson & Johnson Innovation u2013 JJDC, Inc., to further develop its BioTraceu2122 system, an image analysis system for predicting post-treatment ablation morphology in real time.
2019-05

Frequently Asked Questions

Techsomed's core offering is the BioTraceu2122 platform, an AI-powered software suite designed for image-guided thermal ablation therapy. It provides interventional radiologists with real-time visualization, predictive margin control, and dynamic treatment planning for liver and kidney tumor ablations, aiming to enhance precision and improve outcomes.
Techsomed's BioTrace platform leverages generative AI and advanced image analysis to integrate data from ultrasound, CT, and MRI, offering real-time visualization of the ablation zone and predictive modeling of tissue response. This enables personalized treatment planning and assessment, transforming thermal ablation from guesswork into precise, feedback-dependent treatments.
Techsomed has received FDA 510(k) clearance for its VisAble.IO software for planning and confirming liver ablation procedures. Additionally, its BioTraceIO software received De Novo clearance as the first ultrasound-based solution for tissue response prediction in liver tumor ablation, and most recently, BioTraceIO360 received 510(k) clearance for kidney ablation.
Yes, Techsomed explicitly states its dedication to making an enhanced clinical impact in oncology, cardiology (for heart arrhythmia), and pain management through its AI-powered image-guided ablation therapy system. While current FDA clearances are for liver and kidney, their technology is designed to be applicable to these broader fields.
Techsomed has formed significant partnerships, including a pilot collaboration with Medtronic to integrate BioTraceIO360 with the Emprint microwave ablation system, and field evaluations with GE HealthCare ultrasound systems. These collaborations aim to provide comprehensive, integrated solutions for image-guided ablation, enhancing workflow and treatment precision for interventional radiologists.
The BioTrace platform is designed to be hardware-agnostic, integrating with standard commercial ultrasound, CT, and MRI imaging systems. This allows for real-time visualization and analysis of tissue viability during thermal ablation procedures, providing a unified workflow for planning, execution, and monitoring.
Techsomed is a Series B company, founded in 2012, with approximately $9.6M in funding from investors like Johnson & Johnson Innovation. Their strategic partnerships with industry leaders like Medtronic and GE HealthCare, along with a research collaboration with Fraunhofer MEVIS, indicate strong market validation and a commitment to ongoing development and support for their innovative AI-driven solutions.

Related Companies

Google DeepMind is a leading artificial intelligence (AI) research laboratory, a subsidiary of Alphabet Inc., dedicated to developing advanced AI systems to benefit humanity. The company focuses on creating general-purpose AI that can learn and solve complex problems, drawing inspiration from neuroscience and machine learning. Their work spans various fields, including healthcare, scientific discovery, and […]

TalkToMedi is a Canadian healthcare AI company that has developed a clinical-grade voice AI platform called MEDI. This platform is designed to automate patient communication and administrative tasks for medical clinics, including family medicine, specialty clinics, allied health, and physiotherapy. MEDI handles high-volume patient calls, automating appointment inquiries, booking, rescheduling, and cancellations based on the […]

Menaela is an AI-first practice management system designed for solo practitioners, small private clinics, and clinic owners. It integrates patient communication, scheduling, CRM, and medical documentation into a single platform, aiming to replace multiple disconnected tools and bots. The system features an AI practice manager that understands natural-language requests, utilizes real clinic data, and performs […]

Avie is operated by AVIE TECNOLOGIA LTDA, headquartered in Santo André, São Paulo, Brazil. Avie provides WhatsApp reception in Brazilian Portuguese, appointment scheduling, rescheduling and cancellations through Google Calendar or Feegow, clinic CRM, follow-up messages and an online booking website. Clinic staff can review conversations and take over when human support is needed. Clinic CRM […]

Saile is a physician-founded healthcare technology company that addresses critical inefficiencies in healthcare staffing and credentialing. Their AI-powered platform acts as a “universal credential passport” for physicians, centralizing and managing all medical licenses, certifications, and CME credits in one secure, portable vault. This system aims to significantly reduce the administrative burden and delays associated with […]

Data Capture Experts (DCE) is an Australian-based healthcare AI company that is at the forefront of digital health transformation. They specialize in developing and implementing digital health platforms that integrate data, technology, and human-centered design to create intuitive and connected healthcare systems. Their flagship platform, DC2Vue, is designed to go beyond traditional Electronic Medical Records […]

AI Tool Finder
AI-powered search. Results may not be comprehensive.